Li Junsheng, Ge Peicong, He Qiheng, Liu Chenglong, Zeng Chaofan, Tao Chuming, Zhai Yuanren, Wang Jia, Zhang Qian, Wang Rong, Zhang Yan, Zhang Dong, Zhao Jizong
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing, China.
Front Neurosci. 2023 Apr 12;17:1158111. doi: 10.3389/fnins.2023.1158111. eCollection 2023.
Methionine sulfoxide (MetO) has been identified as a risk factor for vascular diseases and was considered as an important indicator of oxidative stress. However, the effects of MetO and its association with moyamoya disease (MMD) remained unclear. Therefore, we performed this study to evaluate the association between serum MetO levels and the risk of MMD and its subtypes.
We eventually included consecutive 353 MMD patients and 88 healthy controls (HCs) with complete data from September 2020 to December 2021 in our analyzes. Serum levels of MetO were quantified using liquid chromatography-mass spectrometry (LC-MS) analysis. We evaluated the role of MetO in MMD using logistic regression models and confirmed by receiver-operating characteristic (ROC) curves and area under curve (AUC) values.
We found that the levels of MetO were significantly higher in MMD and its subtypes than in HCs ( < 0.001 for all). After adjusting for traditional risk factors, serum MetO levels were significantly associated with the risk of MMD and its subtypes (p < 0.001 for all). We further divided the MetO levels into low and high groups, and the high MetO level was significantly associated with the risk of MMD and its subtypes ( < 0.05 for all). When MetO levels were assessed as quartiles, we found that the third (Q3) and fourth (Q4) MetO quartiles had a significantly increased risk of MMD compared with the lowest quartile (Q3, OR: 2.323, 95%CI: 1.088-4.959, = 0.029; Q4, OR: 5.559, 95%CI: 2.088-14.805, = 0.001).
In this study, we found that a high level of serum MetO was associated with an increased risk of MMD and its subtypes. Our study raised a novel perspective on the pathogenesis of MMD and suggested potential therapeutic targets.
甲硫氨酸亚砜（MetO）已被确定为血管疾病的危险因素，并被视为氧化应激的重要指标。然而，MetO的影响及其与烟雾病（MMD）的关联仍不清楚。因此，我们进行了这项研究，以评估血清MetO水平与MMD及其亚型风险之间的关联。
我们最终纳入了2020年9月至2021年12月期间连续的353例MMD患者和88例健康对照（HCs），并对其进行完整数据分析。使用液相色谱-质谱（LC-MS）分析对血清MetO水平进行定量。我们使用逻辑回归模型评估MetO在MMD中的作用，并通过受试者工作特征（ROC）曲线和曲线下面积（AUC）值进行确认。
我们发现，MMD及其亚型中MetO水平显著高于HCs（所有比较p均<0.001）。在调整传统危险因素后，血清MetO水平与MMD及其亚型风险显著相关（所有比较p均<0.001）。我们进一步将MetO水平分为低水平组和高水平组，高水平MetO与MMD及其亚型风险显著相关（所有比较p均<0.05）。当将MetO水平评估为四分位数时，我们发现与最低四分位数相比，第三（Q3）和第四（Q4）MetO四分位数的MMD风险显著增加（Q3，OR：2.323，95%CI：1.088-4.959，p=0.029；Q4，OR：5.559，95%CI：2.088-14.805，p=0.001）。
在本研究中，我们发现血清MetO高水平与MMD及其亚型风险增加相关。我们的研究为MMD的发病机制提出了新的观点，并提示了潜在的治疗靶点。
